nodes	percent_of_prediction	percent_of_DWPC	metapath
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA4—prostate cancer	0.0187	0.0978	CbGpPWpGaD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA3—prostate cancer	0.0171	0.0894	CbGpPWpGaD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—HPGD—prostate cancer	0.012	0.063	CbGpPWpGaD
Travoprost—PTGFR—Small Ligand GPCRs—LPAR1—prostate cancer	0.0108	0.0567	CbGpPWpGaD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—TBXAS1—prostate cancer	0.00834	0.0437	CbGpPWpGaD
Travoprost—PTGFR—prostate gland—prostate cancer	0.00762	0.412	CbGeAlD
Travoprost—Bimatoprost—AKR1C3—prostate cancer	0.00665	0.378	CrCbGaD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA1—prostate cancer	0.00553	0.0289	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Other—GRPR—prostate cancer	0.00513	0.0268	CbGpPWpGaD
Travoprost—PTGFR—urethra—prostate cancer	0.0051	0.276	CbGeAlD
Travoprost—Dinoprost Tromethamine—HPGDS—prostate cancer	0.00494	0.281	CrCbGaD
Travoprost—Latanoprost—SLC22A1—prostate cancer	0.00429	0.244	CrCbGaD
Travoprost—PTGFR—testis—prostate cancer	0.00336	0.181	CbGeAlD
Travoprost—PTGFR—G alpha (q) signalling events—GRPR—prostate cancer	0.00288	0.0151	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GRPR—prostate cancer	0.00258	0.0135	CbGpPWpGaD
Travoprost—PTGFR—lymph node—prostate cancer	0.00243	0.131	CbGeAlD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—GRPR—prostate cancer	0.00223	0.0117	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—RLN2—prostate cancer	0.00217	0.0114	CbGpPWpGaD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—prostate cancer	0.00216	0.0113	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—GRPR—prostate cancer	0.00191	0.00999	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—MC2R—prostate cancer	0.00183	0.00958	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—GNRH1—prostate cancer	0.00179	0.00939	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Other—ADRB2—prostate cancer	0.00178	0.00934	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—GRP—prostate cancer	0.00174	0.0091	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—LPAR1—prostate cancer	0.00174	0.0091	CbGpPWpGaD
Travoprost—Tafluprost—PTGS2—prostate cancer	0.00173	0.098	CrCbGaD
Travoprost—PTGFR—G alpha (q) signalling events—PLCB2—prostate cancer	0.00172	0.009	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—RLN2—prostate cancer	0.00165	0.00864	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—prostate cancer	0.0016	0.0084	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—MC2R—prostate cancer	0.00157	0.00821	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—GNG5—prostate cancer	0.00156	0.00817	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—LPAR1—prostate cancer	0.00155	0.00813	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—prostate cancer	0.00155	0.00813	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PLCB2—prostate cancer	0.00154	0.00805	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—GRPR—prostate cancer	0.00145	0.00761	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—PENK—prostate cancer	0.0014	0.00731	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GNG5—prostate cancer	0.0014	0.00731	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—ANXA1—prostate cancer	0.00128	0.00669	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—WNT4—prostate cancer	0.00125	0.00655	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—OR51E2—prostate cancer	0.00123	0.00645	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—MC2R—prostate cancer	0.00119	0.00625	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—GNRH1—prostate cancer	0.00119	0.00622	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—GRP—prostate cancer	0.00115	0.00602	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—LPAR1—prostate cancer	0.00115	0.00602	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—prostate cancer	0.00114	0.00599	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—OR51E2—prostate cancer	0.00112	0.00585	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CX3CL1—prostate cancer	0.00112	0.00585	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—PRKCQ—prostate cancer	0.00107	0.00559	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—PENK—prostate cancer	0.00106	0.00557	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—RGS17—prostate cancer	0.00105	0.00548	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCQ—prostate cancer	0.000954	0.005	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—RGS17—prostate cancer	0.000951	0.00498	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—ITPR1—prostate cancer	0.000949	0.00497	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—RLN2—prostate cancer	0.000933	0.00489	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—GNRH1—prostate cancer	0.000905	0.00474	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—LPAR1—prostate cancer	0.000876	0.00459	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—GRP—prostate cancer	0.000876	0.00459	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PLXNB1—prostate cancer	0.000854	0.00447	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CX3CL1—prostate cancer	0.000851	0.00445	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—prostate cancer	0.000849	0.00444	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—RLN2—prostate cancer	0.000847	0.00444	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—ANXA1—prostate cancer	0.000847	0.00443	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—GRPR—prostate cancer	0.000822	0.0043	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—GNG5—prostate cancer	0.000787	0.00412	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—ADRB2—prostate cancer	0.000775	0.00406	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PLXNB1—prostate cancer	0.000775	0.00406	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL12—prostate cancer	0.000774	0.00405	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GRPR—prostate cancer	0.000746	0.00391	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—PTHLH—prostate cancer	0.000686	0.00359	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—MC2R—prostate cancer	0.000675	0.00353	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	0.000664	0.00348	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—OR51E2—prostate cancer	0.000661	0.00346	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—ANXA1—prostate cancer	0.000645	0.00337	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—WNT4—prostate cancer	0.000642	0.00336	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—MC2R—prostate cancer	0.000613	0.00321	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—BMPR1B—prostate cancer	0.000604	0.00316	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CALCA—prostate cancer	0.000604	0.00316	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PENK—prostate cancer	0.000601	0.00315	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CXCL12—prostate cancer	0.00059	0.00309	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RGS17—prostate cancer	0.000562	0.00294	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PENK—prostate cancer	0.000546	0.00286	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—prostate cancer	0.000521	0.00273	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—VIP—prostate cancer	0.000511	0.00268	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—GNRH1—prostate cancer	0.000511	0.00268	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—ADRB2—prostate cancer	0.000506	0.00265	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RLN2—prostate cancer	0.000501	0.00262	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—LPAR1—prostate cancer	0.000495	0.00259	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—GRP—prostate cancer	0.000495	0.00259	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PLCB2—prostate cancer	0.00049	0.00257	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CTBP2—prostate cancer	0.000478	0.0025	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HSD17B1—prostate cancer	0.000478	0.0025	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—prostate cancer	0.000475	0.00249	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PDE4D—prostate cancer	0.000468	0.00245	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—VIP—prostate cancer	0.000464	0.00243	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GNRH1—prostate cancer	0.000464	0.00243	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PLXNB1—prostate cancer	0.000458	0.0024	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—LPAR1—prostate cancer	0.00045	0.00235	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GRP—prostate cancer	0.00045	0.00235	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PLCB2—prostate cancer	0.000445	0.00233	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—GNG5—prostate cancer	0.000445	0.00233	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GRPR—prostate cancer	0.000441	0.00231	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CX3CL1—prostate cancer	0.000437	0.00229	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL17RD—prostate cancer	0.000426	0.00223	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PDE4D—prostate cancer	0.000425	0.00222	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GNG5—prostate cancer	0.000404	0.00211	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PTHLH—prostate cancer	0.000388	0.00203	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—WNT4—prostate cancer	0.000379	0.00199	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—JUP—prostate cancer	0.000379	0.00199	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—ANXA1—prostate cancer	0.000364	0.00191	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RALBP1—prostate cancer	0.000362	0.00189	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MC2R—prostate cancer	0.000362	0.00189	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PTHLH—prostate cancer	0.000352	0.00184	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PRKACB—prostate cancer	0.000344	0.0018	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CALCA—prostate cancer	0.000341	0.00179	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PPP3CA—prostate cancer	0.000336	0.00176	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCL12—prostate cancer	0.000333	0.00174	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—ANXA1—prostate cancer	0.000331	0.00173	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PENK—prostate cancer	0.000323	0.00169	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	0.000321	0.00168	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	0.000317	0.00166	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CALCA—prostate cancer	0.00031	0.00162	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GHR—prostate cancer	0.000308	0.00161	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—PIK3CA—prostate cancer	0.000307	0.00161	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PRKCQ—prostate cancer	0.000304	0.00159	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCL12—prostate cancer	0.000303	0.00158	CbGpPWpGaD
Travoprost—Diarrhoea—Estradiol—prostate cancer	0.000301	0.00039	CcSEcCtD
Travoprost—Hypertension—Docetaxel—prostate cancer	0.0003	0.000388	CcSEcCtD
Travoprost—Infestation—Epirubicin—prostate cancer	0.0003	0.000388	CcSEcCtD
Travoprost—Infestation NOS—Epirubicin—prostate cancer	0.0003	0.000388	CcSEcCtD
Travoprost—Erythema—Prednisone—prostate cancer	0.0003	0.000388	CcSEcCtD
Travoprost—Bronchitis—Doxorubicin—prostate cancer	0.0003	0.000388	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	0.000299	0.00157	CbGpPWpGaD
Travoprost—Palpitations—Capecitabine—prostate cancer	0.000298	0.000385	CcSEcCtD
Travoprost—Arthralgia—Docetaxel—prostate cancer	0.000296	0.000383	CcSEcCtD
Travoprost—Chest pain—Docetaxel—prostate cancer	0.000296	0.000383	CcSEcCtD
Travoprost—Myalgia—Docetaxel—prostate cancer	0.000296	0.000383	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—NRP1—prostate cancer	0.000295	0.00154	CbGpPWpGaD
Travoprost—Gastrointestinal disorder—Etoposide—prostate cancer	0.000295	0.000381	CcSEcCtD
Travoprost—Asthenia—Mitoxantrone—prostate cancer	0.000295	0.000381	CcSEcCtD
Travoprost—Fatigue—Etoposide—prostate cancer	0.000294	0.000381	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000294	0.00038	CcSEcCtD
Travoprost—Cough—Capecitabine—prostate cancer	0.000294	0.00038	CcSEcCtD
Travoprost—Pain—Etoposide—prostate cancer	0.000292	0.000378	CcSEcCtD
Travoprost—Constipation—Etoposide—prostate cancer	0.000292	0.000378	CcSEcCtD
Travoprost—Conjunctivitis—Epirubicin—prostate cancer	0.000292	0.000377	CcSEcCtD
Travoprost—Urinary tract infection—Epirubicin—prostate cancer	0.000292	0.000377	CcSEcCtD
Travoprost—Dizziness—Estradiol—prostate cancer	0.000291	0.000377	CcSEcCtD
Travoprost—Dysuria—Doxorubicin—prostate cancer	0.000291	0.000377	CcSEcCtD
Travoprost—Hypertension—Capecitabine—prostate cancer	0.000291	0.000376	CcSEcCtD
Travoprost—Dry mouth—Docetaxel—prostate cancer	0.00029	0.000375	CcSEcCtD
Travoprost—Arthralgia—Capecitabine—prostate cancer	0.000287	0.000371	CcSEcCtD
Travoprost—Myalgia—Capecitabine—prostate cancer	0.000287	0.000371	CcSEcCtD
Travoprost—Chest pain—Capecitabine—prostate cancer	0.000287	0.000371	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—ADRB2—prostate cancer	0.000286	0.0015	CbGpPWpGaD
Travoprost—Anxiety—Capecitabine—prostate cancer	0.000286	0.00037	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000285	0.000368	CcSEcCtD
Travoprost—Oedema—Docetaxel—prostate cancer	0.000284	0.000367	CcSEcCtD
Travoprost—Discomfort—Capecitabine—prostate cancer	0.000283	0.000366	CcSEcCtD
Travoprost—Vision blurred—Prednisone—prostate cancer	0.000283	0.000366	CcSEcCtD
Travoprost—Infection—Docetaxel—prostate cancer	0.000282	0.000365	CcSEcCtD
Travoprost—Sinusitis—Epirubicin—prostate cancer	0.000282	0.000364	CcSEcCtD
Travoprost—Feeling abnormal—Etoposide—prostate cancer	0.000281	0.000364	CcSEcCtD
Travoprost—Diarrhoea—Mitoxantrone—prostate cancer	0.000281	0.000363	CcSEcCtD
Travoprost—Dry mouth—Capecitabine—prostate cancer	0.00028	0.000363	CcSEcCtD
Travoprost—Gastrointestinal pain—Etoposide—prostate cancer	0.000279	0.000361	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—VAV3—prostate cancer	0.000279	0.00146	CbGpPWpGaD
Travoprost—Nervous system disorder—Docetaxel—prostate cancer	0.000278	0.00036	CcSEcCtD
Travoprost—Ill-defined disorder—Prednisone—prostate cancer	0.000278	0.00036	CcSEcCtD
Travoprost—Rash—Estradiol—prostate cancer	0.000278	0.000359	CcSEcCtD
Travoprost—Infestation NOS—Doxorubicin—prostate cancer	0.000278	0.000359	CcSEcCtD
Travoprost—Infestation—Doxorubicin—prostate cancer	0.000278	0.000359	CcSEcCtD
Travoprost—Dermatitis—Estradiol—prostate cancer	0.000278	0.000359	CcSEcCtD
Travoprost—Tachycardia—Docetaxel—prostate cancer	0.000277	0.000358	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—PRKCQ—prostate cancer	0.000276	0.00145	CbGpPWpGaD
Travoprost—Headache—Estradiol—prostate cancer	0.000276	0.000357	CcSEcCtD
Travoprost—Skin disorder—Docetaxel—prostate cancer	0.000276	0.000357	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	0.000275	0.00144	CbGpPWpGaD
Travoprost—Oedema—Capecitabine—prostate cancer	0.000275	0.000356	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—GNRH1—prostate cancer	0.000274	0.00144	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VIP—prostate cancer	0.000274	0.00144	CbGpPWpGaD
Travoprost—Bradycardia—Epirubicin—prostate cancer	0.000274	0.000355	CcSEcCtD
Travoprost—Infection—Capecitabine—prostate cancer	0.000273	0.000353	CcSEcCtD
Travoprost—Malaise—Prednisone—prostate cancer	0.00027	0.00035	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—ITPR1—prostate cancer	0.00027	0.00142	CbGpPWpGaD
Travoprost—Rhinitis—Epirubicin—prostate cancer	0.00027	0.00035	CcSEcCtD
Travoprost—Abdominal pain—Etoposide—prostate cancer	0.00027	0.000349	CcSEcCtD
Travoprost—Urinary tract infection—Doxorubicin—prostate cancer	0.00027	0.000349	CcSEcCtD
Travoprost—Conjunctivitis—Doxorubicin—prostate cancer	0.00027	0.000349	CcSEcCtD
Travoprost—Nervous system disorder—Capecitabine—prostate cancer	0.000269	0.000349	CcSEcCtD
Travoprost—Vertigo—Prednisone—prostate cancer	0.000269	0.000349	CcSEcCtD
Travoprost—Tachycardia—Capecitabine—prostate cancer	0.000268	0.000347	CcSEcCtD
Travoprost—Pharyngitis—Epirubicin—prostate cancer	0.000267	0.000346	CcSEcCtD
Travoprost—Skin disorder—Capecitabine—prostate cancer	0.000267	0.000345	CcSEcCtD
Travoprost—Urinary tract disorder—Epirubicin—prostate cancer	0.000266	0.000344	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—GRP—prostate cancer	0.000266	0.00139	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LPAR1—prostate cancer	0.000266	0.00139	CbGpPWpGaD
Travoprost—Hypotension—Docetaxel—prostate cancer	0.000265	0.000343	CcSEcCtD
Travoprost—Connective tissue disorder—Epirubicin—prostate cancer	0.000265	0.000343	CcSEcCtD
Travoprost—Urethral disorder—Epirubicin—prostate cancer	0.000264	0.000342	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PLCB2—prostate cancer	0.000263	0.00138	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LRP2—prostate cancer	0.000263	0.00138	CbGpPWpGaD
Travoprost—Nausea—Estradiol—prostate cancer	0.000262	0.000339	CcSEcCtD
Travoprost—Sinusitis—Doxorubicin—prostate cancer	0.000261	0.000337	CcSEcCtD
Travoprost—Visual impairment—Epirubicin—prostate cancer	0.00026	0.000336	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—ADRB2—prostate cancer	0.00026	0.00136	CbGpPWpGaD
Travoprost—Hypertension—Prednisone—prostate cancer	0.000259	0.000335	CcSEcCtD
Travoprost—Rash—Mitoxantrone—prostate cancer	0.000259	0.000335	CcSEcCtD
Travoprost—Dermatitis—Mitoxantrone—prostate cancer	0.000259	0.000335	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000259	0.000335	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—P4HB—prostate cancer	0.000258	0.00135	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CX3CL1—prostate cancer	0.000258	0.00135	CbGpPWpGaD
Travoprost—Headache—Mitoxantrone—prostate cancer	0.000257	0.000333	CcSEcCtD
Travoprost—Hypotension—Capecitabine—prostate cancer	0.000257	0.000332	CcSEcCtD
Travoprost—Myalgia—Prednisone—prostate cancer	0.000255	0.00033	CcSEcCtD
Travoprost—Arthralgia—Prednisone—prostate cancer	0.000255	0.00033	CcSEcCtD
Travoprost—Anxiety—Prednisone—prostate cancer	0.000254	0.000329	CcSEcCtD
Travoprost—Bradycardia—Doxorubicin—prostate cancer	0.000254	0.000328	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000254	0.000328	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—VAV3—prostate cancer	0.000253	0.00133	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HIST1H2BG—prostate cancer	0.000253	0.00133	CbGpPWpGaD
Travoprost—Dyspnoea—Docetaxel—prostate cancer	0.000253	0.000327	CcSEcCtD
Travoprost—Discomfort—Prednisone—prostate cancer	0.000252	0.000326	CcSEcCtD
Travoprost—Eye disorder—Epirubicin—prostate cancer	0.000252	0.000326	CcSEcCtD
Travoprost—Hypersensitivity—Etoposide—prostate cancer	0.000252	0.000326	CcSEcCtD
Travoprost—Tinnitus—Epirubicin—prostate cancer	0.000251	0.000325	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—GRB7—prostate cancer	0.000251	0.00131	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PDE4D—prostate cancer	0.000251	0.00131	CbGpPWpGaD
Travoprost—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.00025	0.000324	CcSEcCtD
Travoprost—Cardiac disorder—Epirubicin—prostate cancer	0.00025	0.000324	CcSEcCtD
Travoprost—Rhinitis—Doxorubicin—prostate cancer	0.00025	0.000323	CcSEcCtD
Travoprost—Dyspepsia—Docetaxel—prostate cancer	0.00025	0.000323	CcSEcCtD
Travoprost—Pharyngitis—Doxorubicin—prostate cancer	0.000247	0.00032	CcSEcCtD
Travoprost—Urinary tract disorder—Doxorubicin—prostate cancer	0.000246	0.000319	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—ITPR1—prostate cancer	0.000246	0.00129	CbGpPWpGaD
Travoprost—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000245	0.000317	CcSEcCtD
Travoprost—Asthenia—Etoposide—prostate cancer	0.000245	0.000317	CcSEcCtD
Travoprost—Connective tissue disorder—Doxorubicin—prostate cancer	0.000245	0.000317	CcSEcCtD
Travoprost—Dyspnoea—Capecitabine—prostate cancer	0.000245	0.000317	CcSEcCtD
Travoprost—Oedema—Prednisone—prostate cancer	0.000245	0.000317	CcSEcCtD
Travoprost—Fatigue—Docetaxel—prostate cancer	0.000245	0.000317	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—HIST1H4H—prostate cancer	0.000244	0.00128	CbGpPWpGaD
Travoprost—Angiopathy—Epirubicin—prostate cancer	0.000244	0.000316	CcSEcCtD
Travoprost—Urethral disorder—Doxorubicin—prostate cancer	0.000244	0.000316	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CXCL8—prostate cancer	0.000244	0.00128	CbGpPWpGaD
Travoprost—Nausea—Mitoxantrone—prostate cancer	0.000244	0.000316	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	0.000243	0.00127	CbGpPWpGaD
Travoprost—Immune system disorder—Epirubicin—prostate cancer	0.000243	0.000315	CcSEcCtD
Travoprost—Infection—Prednisone—prostate cancer	0.000243	0.000315	CcSEcCtD
Travoprost—Mediastinal disorder—Epirubicin—prostate cancer	0.000243	0.000314	CcSEcCtD
Travoprost—Pain—Docetaxel—prostate cancer	0.000243	0.000314	CcSEcCtD
Travoprost—Constipation—Docetaxel—prostate cancer	0.000243	0.000314	CcSEcCtD
Travoprost—Dyspepsia—Capecitabine—prostate cancer	0.000242	0.000313	CcSEcCtD
Travoprost—Pruritus—Etoposide—prostate cancer	0.000242	0.000313	CcSEcCtD
Travoprost—Visual impairment—Doxorubicin—prostate cancer	0.00024	0.000311	CcSEcCtD
Travoprost—Nervous system disorder—Prednisone—prostate cancer	0.00024	0.000311	CcSEcCtD
Travoprost—Tachycardia—Prednisone—prostate cancer	0.000239	0.000309	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—GNG5—prostate cancer	0.000239	0.00125	CbGpPWpGaD
Travoprost—Skin disorder—Prednisone—prostate cancer	0.000238	0.000308	CcSEcCtD
Travoprost—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000237	0.000307	CcSEcCtD
Travoprost—Fatigue—Capecitabine—prostate cancer	0.000237	0.000307	CcSEcCtD
Travoprost—Mental disorder—Epirubicin—prostate cancer	0.000236	0.000305	CcSEcCtD
Travoprost—Constipation—Capecitabine—prostate cancer	0.000235	0.000304	CcSEcCtD
Travoprost—Pain—Capecitabine—prostate cancer	0.000235	0.000304	CcSEcCtD
Travoprost—Erythema—Epirubicin—prostate cancer	0.000235	0.000303	CcSEcCtD
Travoprost—Feeling abnormal—Docetaxel—prostate cancer	0.000234	0.000303	CcSEcCtD
Travoprost—Diarrhoea—Etoposide—prostate cancer	0.000234	0.000302	CcSEcCtD
Travoprost—Eye disorder—Doxorubicin—prostate cancer	0.000233	0.000301	CcSEcCtD
Travoprost—Tinnitus—Doxorubicin—prostate cancer	0.000232	0.000301	CcSEcCtD
Travoprost—Gastrointestinal pain—Docetaxel—prostate cancer	0.000232	0.0003	CcSEcCtD
Travoprost—Cardiac disorder—Doxorubicin—prostate cancer	0.000231	0.000299	CcSEcCtD
Travoprost—Dysgeusia—Epirubicin—prostate cancer	0.00023	0.000297	CcSEcCtD
Travoprost—Back pain—Epirubicin—prostate cancer	0.000227	0.000294	CcSEcCtD
Travoprost—Feeling abnormal—Capecitabine—prostate cancer	0.000226	0.000293	CcSEcCtD
Travoprost—Angiopathy—Doxorubicin—prostate cancer	0.000226	0.000293	CcSEcCtD
Travoprost—Dizziness—Etoposide—prostate cancer	0.000226	0.000292	CcSEcCtD
Travoprost—Immune system disorder—Doxorubicin—prostate cancer	0.000225	0.000291	CcSEcCtD
Travoprost—Gastrointestinal pain—Capecitabine—prostate cancer	0.000225	0.000291	CcSEcCtD
Travoprost—Mediastinal disorder—Doxorubicin—prostate cancer	0.000225	0.000291	CcSEcCtD
Travoprost—Abdominal pain—Docetaxel—prostate cancer	0.000224	0.00029	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000223	0.000289	CcSEcCtD
Travoprost—Vision blurred—Epirubicin—prostate cancer	0.000221	0.000286	CcSEcCtD
Travoprost—Mental disorder—Doxorubicin—prostate cancer	0.000218	0.000283	CcSEcCtD
Travoprost—Ill-defined disorder—Epirubicin—prostate cancer	0.000218	0.000282	CcSEcCtD
Travoprost—Abdominal pain—Capecitabine—prostate cancer	0.000217	0.000281	CcSEcCtD
Travoprost—Erythema—Doxorubicin—prostate cancer	0.000217	0.000281	CcSEcCtD
Travoprost—Dyspepsia—Prednisone—prostate cancer	0.000215	0.000279	CcSEcCtD
Travoprost—Rash—Etoposide—prostate cancer	0.000215	0.000279	CcSEcCtD
Travoprost—Dermatitis—Etoposide—prostate cancer	0.000215	0.000278	CcSEcCtD
Travoprost—Headache—Etoposide—prostate cancer	0.000214	0.000277	CcSEcCtD
Travoprost—Dysgeusia—Doxorubicin—prostate cancer	0.000213	0.000275	CcSEcCtD
Travoprost—Malaise—Epirubicin—prostate cancer	0.000212	0.000274	CcSEcCtD
Travoprost—Fatigue—Prednisone—prostate cancer	0.000211	0.000273	CcSEcCtD
Travoprost—Vertigo—Epirubicin—prostate cancer	0.000211	0.000273	CcSEcCtD
Travoprost—Back pain—Doxorubicin—prostate cancer	0.00021	0.000272	CcSEcCtD
Travoprost—Constipation—Prednisone—prostate cancer	0.000209	0.000271	CcSEcCtD
Travoprost—Hypersensitivity—Docetaxel—prostate cancer	0.000209	0.000271	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PTHLH—prostate cancer	0.000208	0.00109	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TGFBR1—prostate cancer	0.000208	0.00109	CbGpPWpGaD
Travoprost—Palpitations—Epirubicin—prostate cancer	0.000207	0.000268	CcSEcCtD
Travoprost—Cough—Epirubicin—prostate cancer	0.000205	0.000265	CcSEcCtD
Travoprost—Vision blurred—Doxorubicin—prostate cancer	0.000205	0.000265	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—AKR1C3—prostate cancer	0.000205	0.00107	CbGpPWpGaD
Travoprost—Asthenia—Docetaxel—prostate cancer	0.000204	0.000263	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PRKACB—prostate cancer	0.000203	0.00106	CbGpPWpGaD
Travoprost—Nausea—Etoposide—prostate cancer	0.000203	0.000262	CcSEcCtD
Travoprost—Hypertension—Epirubicin—prostate cancer	0.000202	0.000262	CcSEcCtD
Travoprost—Hypersensitivity—Capecitabine—prostate cancer	0.000202	0.000262	CcSEcCtD
Travoprost—Feeling abnormal—Prednisone—prostate cancer	0.000202	0.000261	CcSEcCtD
Travoprost—Ill-defined disorder—Doxorubicin—prostate cancer	0.000201	0.000261	CcSEcCtD
Travoprost—Pruritus—Docetaxel—prostate cancer	0.000201	0.00026	CcSEcCtD
Travoprost—Gastrointestinal pain—Prednisone—prostate cancer	0.0002	0.000259	CcSEcCtD
Travoprost—Myalgia—Epirubicin—prostate cancer	0.0002	0.000258	CcSEcCtD
Travoprost—Arthralgia—Epirubicin—prostate cancer	0.0002	0.000258	CcSEcCtD
Travoprost—Chest pain—Epirubicin—prostate cancer	0.0002	0.000258	CcSEcCtD
Travoprost—Anxiety—Epirubicin—prostate cancer	0.000199	0.000257	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PPP3CA—prostate cancer	0.000198	0.00104	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—THBS1—prostate cancer	0.000198	0.00104	CbGpPWpGaD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000198	0.000257	CcSEcCtD
Travoprost—Discomfort—Epirubicin—prostate cancer	0.000197	0.000255	CcSEcCtD
Travoprost—Asthenia—Capecitabine—prostate cancer	0.000197	0.000255	CcSEcCtD
Travoprost—Malaise—Doxorubicin—prostate cancer	0.000196	0.000253	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—ANXA1—prostate cancer	0.000195	0.00102	CbGpPWpGaD
Travoprost—Dry mouth—Epirubicin—prostate cancer	0.000195	0.000253	CcSEcCtD
Travoprost—Vertigo—Doxorubicin—prostate cancer	0.000195	0.000252	CcSEcCtD
Travoprost—Pruritus—Capecitabine—prostate cancer	0.000194	0.000252	CcSEcCtD
Travoprost—Diarrhoea—Docetaxel—prostate cancer	0.000194	0.000251	CcSEcCtD
Travoprost—Abdominal pain—Prednisone—prostate cancer	0.000193	0.00025	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PRKCZ—prostate cancer	0.000192	0.001	CbGpPWpGaD
Travoprost—Palpitations—Doxorubicin—prostate cancer	0.000192	0.000248	CcSEcCtD
Travoprost—Oedema—Epirubicin—prostate cancer	0.000191	0.000248	CcSEcCtD
Travoprost—Infection—Epirubicin—prostate cancer	0.00019	0.000246	CcSEcCtD
Travoprost—Cough—Doxorubicin—prostate cancer	0.000189	0.000245	CcSEcCtD
Travoprost—Diarrhoea—Capecitabine—prostate cancer	0.000188	0.000243	CcSEcCtD
Travoprost—Nervous system disorder—Epirubicin—prostate cancer	0.000188	0.000243	CcSEcCtD
Travoprost—Dizziness—Docetaxel—prostate cancer	0.000188	0.000243	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CG—prostate cancer	0.000188	0.000982	CbGpPWpGaD
Travoprost—Hypertension—Doxorubicin—prostate cancer	0.000187	0.000242	CcSEcCtD
Travoprost—Tachycardia—Epirubicin—prostate cancer	0.000187	0.000242	CcSEcCtD
Travoprost—Skin disorder—Epirubicin—prostate cancer	0.000186	0.000241	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PARP1—prostate cancer	0.000185	0.00097	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FGFR4—prostate cancer	0.000185	0.00097	CbGpPWpGaD
Travoprost—Myalgia—Doxorubicin—prostate cancer	0.000185	0.000239	CcSEcCtD
Travoprost—Arthralgia—Doxorubicin—prostate cancer	0.000185	0.000239	CcSEcCtD
Travoprost—Chest pain—Doxorubicin—prostate cancer	0.000185	0.000239	CcSEcCtD
Travoprost—Anxiety—Doxorubicin—prostate cancer	0.000184	0.000238	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000183	0.000237	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CALCA—prostate cancer	0.000183	0.000958	CbGpPWpGaD
Travoprost—Discomfort—Doxorubicin—prostate cancer	0.000183	0.000236	CcSEcCtD
Travoprost—Dizziness—Capecitabine—prostate cancer	0.000182	0.000235	CcSEcCtD
Travoprost—Dry mouth—Doxorubicin—prostate cancer	0.000181	0.000234	CcSEcCtD
Travoprost—Hypersensitivity—Prednisone—prostate cancer	0.00018	0.000233	CcSEcCtD
Travoprost—Rash—Docetaxel—prostate cancer	0.000179	0.000232	CcSEcCtD
Travoprost—Hypotension—Epirubicin—prostate cancer	0.000179	0.000231	CcSEcCtD
Travoprost—Dermatitis—Docetaxel—prostate cancer	0.000179	0.000231	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CXCL12—prostate cancer	0.000179	0.000936	CbGpPWpGaD
Travoprost—Headache—Docetaxel—prostate cancer	0.000178	0.00023	CcSEcCtD
Travoprost—Oedema—Doxorubicin—prostate cancer	0.000177	0.000229	CcSEcCtD
Travoprost—Infection—Doxorubicin—prostate cancer	0.000176	0.000228	CcSEcCtD
Travoprost—Asthenia—Prednisone—prostate cancer	0.000176	0.000227	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000174	0.000226	CcSEcCtD
Travoprost—Nervous system disorder—Doxorubicin—prostate cancer	0.000174	0.000225	CcSEcCtD
Travoprost—Rash—Capecitabine—prostate cancer	0.000173	0.000224	CcSEcCtD
Travoprost—Pruritus—Prednisone—prostate cancer	0.000173	0.000224	CcSEcCtD
Travoprost—Dermatitis—Capecitabine—prostate cancer	0.000173	0.000224	CcSEcCtD
Travoprost—Tachycardia—Doxorubicin—prostate cancer	0.000173	0.000224	CcSEcCtD
Travoprost—Headache—Capecitabine—prostate cancer	0.000172	0.000223	CcSEcCtD
Travoprost—Skin disorder—Doxorubicin—prostate cancer	0.000172	0.000223	CcSEcCtD
Travoprost—Dyspnoea—Epirubicin—prostate cancer	0.000171	0.000221	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—PIK3CG—prostate cancer	0.00017	0.000891	CbGpPWpGaD
Travoprost—Nausea—Docetaxel—prostate cancer	0.000169	0.000218	CcSEcCtD
Travoprost—Dyspepsia—Epirubicin—prostate cancer	0.000168	0.000218	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CASP9—prostate cancer	0.000168	0.000881	CbGpPWpGaD
Travoprost—Diarrhoea—Prednisone—prostate cancer	0.000167	0.000217	CcSEcCtD
Travoprost—Hypotension—Doxorubicin—prostate cancer	0.000166	0.000214	CcSEcCtD
Travoprost—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000165	0.000214	CcSEcCtD
Travoprost—Fatigue—Epirubicin—prostate cancer	0.000165	0.000214	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CD—prostate cancer	0.000165	0.000863	CbGpPWpGaD
Travoprost—Constipation—Epirubicin—prostate cancer	0.000164	0.000212	CcSEcCtD
Travoprost—Pain—Epirubicin—prostate cancer	0.000164	0.000212	CcSEcCtD
Travoprost—Nausea—Capecitabine—prostate cancer	0.000163	0.000211	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PRKCQ—prostate cancer	0.000163	0.000854	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NGFR—prostate cancer	0.000163	0.000854	CbGpPWpGaD
Travoprost—Dizziness—Prednisone—prostate cancer	0.000162	0.000209	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000161	0.000209	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—MAP3K7—prostate cancer	0.000161	0.000844	CbGpPWpGaD
Travoprost—Dyspnoea—Doxorubicin—prostate cancer	0.000158	0.000204	CcSEcCtD
Travoprost—Feeling abnormal—Epirubicin—prostate cancer	0.000158	0.000204	CcSEcCtD
Travoprost—Gastrointestinal pain—Epirubicin—prostate cancer	0.000157	0.000203	CcSEcCtD
Travoprost—Dyspepsia—Doxorubicin—prostate cancer	0.000156	0.000202	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—FGF10—prostate cancer	0.000155	0.000811	CbGpPWpGaD
Travoprost—Rash—Prednisone—prostate cancer	0.000154	0.0002	CcSEcCtD
Travoprost—Dermatitis—Prednisone—prostate cancer	0.000154	0.000199	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—ADRB2—prostate cancer	0.000153	0.000803	CbGpPWpGaD
Travoprost—Headache—Prednisone—prostate cancer	0.000153	0.000198	CcSEcCtD
Travoprost—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000153	0.000198	CcSEcCtD
Travoprost—Fatigue—Doxorubicin—prostate cancer	0.000153	0.000198	CcSEcCtD
Travoprost—Constipation—Doxorubicin—prostate cancer	0.000151	0.000196	CcSEcCtD
Travoprost—Pain—Doxorubicin—prostate cancer	0.000151	0.000196	CcSEcCtD
Travoprost—Abdominal pain—Epirubicin—prostate cancer	0.000151	0.000196	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—JAK2—prostate cancer	0.000151	0.000792	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—MAP2K1—prostate cancer	0.000151	0.000789	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CD—prostate cancer	0.00015	0.000784	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VAV3—prostate cancer	0.00015	0.000783	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TGFBR2—prostate cancer	0.000147	0.000772	CbGpPWpGaD
Travoprost—Feeling abnormal—Doxorubicin—prostate cancer	0.000146	0.000189	CcSEcCtD
Travoprost—Nausea—Prednisone—prostate cancer	0.000145	0.000188	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—ITPR1—prostate cancer	0.000145	0.000759	CbGpPWpGaD
Travoprost—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000145	0.000187	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CB—prostate cancer	0.000144	0.000752	CbGpPWpGaD
Travoprost—Hypersensitivity—Epirubicin—prostate cancer	0.000141	0.000182	CcSEcCtD
Travoprost—Abdominal pain—Doxorubicin—prostate cancer	0.00014	0.000181	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—IGF1R—prostate cancer	0.000139	0.000726	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCL8—prostate cancer	0.000138	0.000723	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—JAK2—prostate cancer	0.000137	0.000719	CbGpPWpGaD
Travoprost—Asthenia—Epirubicin—prostate cancer	0.000137	0.000178	CcSEcCtD
Travoprost—Pruritus—Epirubicin—prostate cancer	0.000135	0.000175	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—LPL—prostate cancer	0.000133	0.000696	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—IL2—prostate cancer	0.000132	0.000691	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PDGFRB—prostate cancer	0.000132	0.00069	CbGpPWpGaD
Travoprost—Diarrhoea—Epirubicin—prostate cancer	0.000131	0.000169	CcSEcCtD
Travoprost—Hypersensitivity—Doxorubicin—prostate cancer	0.00013	0.000169	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—PIK3CB—prostate cancer	0.00013	0.000683	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ITGB3—prostate cancer	0.000128	0.000672	CbGpPWpGaD
Travoprost—Asthenia—Doxorubicin—prostate cancer	0.000127	0.000164	CcSEcCtD
Travoprost—Dizziness—Epirubicin—prostate cancer	0.000127	0.000164	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—CXCL8—prostate cancer	0.000125	0.000656	CbGpPWpGaD
Travoprost—Pruritus—Doxorubicin—prostate cancer	0.000125	0.000162	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—ERBB3—prostate cancer	0.000125	0.000652	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FGFR2—prostate cancer	0.000124	0.000651	CbGpPWpGaD
Travoprost—Diarrhoea—Doxorubicin—prostate cancer	0.000121	0.000157	CcSEcCtD
Travoprost—Rash—Epirubicin—prostate cancer	0.000121	0.000156	CcSEcCtD
Travoprost—Dermatitis—Epirubicin—prostate cancer	0.000121	0.000156	CcSEcCtD
Travoprost—Headache—Epirubicin—prostate cancer	0.00012	0.000155	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—IL2—prostate cancer	0.00012	0.000627	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TERT—prostate cancer	0.000119	0.000625	CbGpPWpGaD
Travoprost—Dizziness—Doxorubicin—prostate cancer	0.000117	0.000152	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—HIF1A—prostate cancer	0.000114	0.000598	CbGpPWpGaD
Travoprost—Nausea—Epirubicin—prostate cancer	0.000114	0.000147	CcSEcCtD
Travoprost—Rash—Doxorubicin—prostate cancer	0.000112	0.000145	CcSEcCtD
Travoprost—Dermatitis—Doxorubicin—prostate cancer	0.000112	0.000144	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—LEP—prostate cancer	0.000111	0.000583	CbGpPWpGaD
Travoprost—Headache—Doxorubicin—prostate cancer	0.000111	0.000144	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CAV1—prostate cancer	0.00011	0.000578	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KDR—prostate cancer	0.000109	0.000572	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ESR1—prostate cancer	0.000106	0.000557	CbGpPWpGaD
Travoprost—Nausea—Doxorubicin—prostate cancer	0.000105	0.000136	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—BAD—prostate cancer	0.000104	0.000544	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CG—prostate cancer	0.000101	0.000527	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—APC—prostate cancer	0.000101	0.000527	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EGF—prostate cancer	9.94e-05	0.000521	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IRS1—prostate cancer	9.94e-05	0.000521	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GSK3B—prostate cancer	9.65e-05	0.000505	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—INS—prostate cancer	9.52e-05	0.000498	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CREBBP—prostate cancer	9.33e-05	0.000488	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IGF1—prostate cancer	9.21e-05	0.000482	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—EGFR—prostate cancer	9.16e-05	0.00048	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAP2K1—prostate cancer	8.9e-05	0.000466	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CD—prostate cancer	8.84e-05	0.000463	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CA—prostate cancer	8.76e-05	0.000459	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SERPINE1—prostate cancer	8.75e-05	0.000458	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—KRAS—prostate cancer	8.66e-05	0.000453	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FGF2—prostate cancer	8.47e-05	0.000443	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NOS3—prostate cancer	8.35e-05	0.000437	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—JAK2—prostate cancer	8.12e-05	0.000425	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CA—prostate cancer	7.95e-05	0.000416	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MDM2—prostate cancer	7.92e-05	0.000415	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ERBB2—prostate cancer	7.81e-05	0.000409	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CB—prostate cancer	7.71e-05	0.000403	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCL8—prostate cancer	7.41e-05	0.000388	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDKN1B—prostate cancer	7.23e-05	0.000379	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—AKT1—prostate cancer	7.16e-05	0.000375	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CASP3—prostate cancer	7.09e-05	0.000371	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL2—prostate cancer	7.08e-05	0.000371	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL6—prostate cancer	7.04e-05	0.000369	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCND1—prostate cancer	6.9e-05	0.000361	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CTNNB1—prostate cancer	6.83e-05	0.000358	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MMP9—prostate cancer	6.7e-05	0.000351	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDKN1A—prostate cancer	6.68e-05	0.000349	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PTEN—prostate cancer	6.66e-05	0.000349	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AKT1—prostate cancer	6.5e-05	0.00034	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EP300—prostate cancer	6.35e-05	0.000333	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SRC—prostate cancer	6.18e-05	0.000323	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VEGFA—prostate cancer	6.02e-05	0.000315	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—STAT3—prostate cancer	5.96e-05	0.000312	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MYC—prostate cancer	5.54e-05	0.00029	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TGFB1—prostate cancer	5.52e-05	0.000289	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EGFR—prostate cancer	5.41e-05	0.000283	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KRAS—prostate cancer	5.11e-05	0.000268	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CA—prostate cancer	4.7e-05	0.000246	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TP53—prostate cancer	4.55e-05	0.000238	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL6—prostate cancer	4.16e-05	0.000218	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AKT1—prostate cancer	3.84e-05	0.000201	CbGpPWpGaD
